GM3 signals regulating TNF-alpha expression are mediated by rictor and Arhgdib in mouse melanoma B16 cells

Oncology

Volumn 73, Issue 5-6, 2008, Pages 430-438

  Wang, Pu ^a   Yang, Xiaoyan ^a   Wu, Peixing ^b   Zhang, Jinghai ^a   Sato, Toshinori ^b   Yamagata, Sadako ^a   Yamagata, Tatsuya ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Arhgdib; Ganglioside; GM3; MTOR; Raptor; Rictor; Tumor necrosis factor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CARRIER PROTEIN; GANGLIOSIDE GM3; GUANOSINE DIPHOSPHATE; LY 303511; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN ARHGDIB; PROTEIN KINASE B; PROTEIN RAPTOR; PROTEIN RICTOR; RAPAMYCIN; REGULATOR PROTEIN; RHO FACTOR; SERINE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; CARRIER PROTEINS; CATTLE; CHROMONES; DISEASE MODELS, ANIMAL; DNA PRIMERS; G(M3) GANGLIOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP PHOSPHOHYDROLASES; MELANOMA, EXPERIMENTAL; MICE; PIPERAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45549090184     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000136801     Document Type: Article

References (34)

1. Hakomori S: Tumor-associated carbohydrate antigens. Annu Rev Immunol 1984;2:103-126.
2. Ladisch S, Wu ZL, Feig S, Ulsh L, Schwartz E, Floutsis G, Wiley F, Lenarsky C, Seeger R: Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 1987;39:73-76.
3. Portoukalian J, David MJ, Gain P, Richard M: Shedding of GD2 ganglioside in patients with retinoblastoma. Int J Cancer 1993;35:948-951.
4. Cheresh DA, Honsik CJ, Staffileno LK, Jung G, Reisfeld RA: Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci USA 1985;82:5155-5159.
5. Portoukalian J, David MJ, Shen X, Richard M, Dubreuil C: Tumor size-dependent elevations of serum gangliosides in patients with head and neck carcinomas. Biochem Int 1989;18:759-765.
6. Ladisch S, Kitada S, Hays EF: Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest 1987;79:1879-1882.
7. Li R, Villacreses N, Ladisch S: Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res 1995;55:211-214.
8. McKallip R, Li R, Ladisch S: Tumor gangliosides inhibit the tumor specific immune response. J Immunol 1999;163:3718-3726.
9. Deng W, Li R, Ladisch S: Influence of cellular ganglioside on tumor formation. J Natl Cancer Inst 2000;92:912-917.
10. Ziegler-Heitbrock HW, Kafferlein E, Haas JG, Meyer N, Strobel M, Weber C, Flieger D: Gangliosides suppress tumor necrosis factor production in human monocytes. J Immunol 1992;148:1753-1758.
11. Jou I, Lee JH, Park SY, Yoon HJ, Joe EH, Park EJ: Gangliosides trigger inflammatory responses via TLR4 in brain glia. Am J Pathol 2006;168:1619-1630.
12. Bemelmans MH, Van Tits LJ, Buurman WA: Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 1996;16:1-11.
13. Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-1725.
14. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-501.
15. Wang P, Wu P, Zhang J, Sato T, Yamagata S, Yamagata T: Positive regulation of tumor necrosis factor alpha by ganglioside GM3 through Akt in mouse melanoma B16 cells. Biochem Biophys Res Commun 2007;356:438-443.
16. Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17:596-603.
17. Guertin DA, Sabatini DM: An expanding role for mTOR in cancer. Trends Mol Med 2005;11:353-361.
18. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K: Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002;110:177-189.
19. Thomas GV: mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev 2006;16:78-84.
20. Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev 2004;18:1926-1945.
21. Inoki K, Li Y, Zhu T, Wu J, Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 2002;4:648-657.
22. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B: SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006;127:125-137.
23. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR, Theodorescu D: RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002;62:6418-6423.
24. Jaffe AB, Hall A: Rho GTPases in transformation and metastasis. Adv Cancer Res 2002;84:57-80.
25. Wang L, Takaku S, Wang P, Hu D, Hyuga S, Sato T, Yamagata S, Yamagata T: Ganglioside GD1a regulation of caveolin-1 and Stim1 expression in mouse FBJ cells: augmented expression of caveolin-1 and stim1 in cells with increased GD1a content. Glycoconj J 2006;23:303-315.
26. Kristof AS, Pacheco-Rodriguez G, Schremmer B, Moss J: LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms. J Pharmacol Exp Ther 2005;314:1134-1143.
27. Harrington LS, Findlay GM, Lamb RF: Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 2005;30:35-42.
28. Hazeki K, Kinoshita S, Matsumura T, Nigorikawa K, Kubo H, Hazeki O: Opposite effects of wortmannin and 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran- 4-one hydrochloride on toll-like receptor-mediated nitric oxide production: negative regulation of nuclear factor-κB by phosphoinositide 3-kinase. Mol Pharmacol 2006;69:1717-1724.
29. Burgering BM, Coffer PJ: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995;376:599-602.
30. Franke TF, Yang S, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN: The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995;81:727-736.
31. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101.
32. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-168.
33. Titus B, Frierson HF Jr, Conaway M, Ching K, Guise T, Chirgwin J, Hampton G, Theodorescu D: Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005;65:7320-7327.
34. Wang P, Wu P, Zhang J, Sato T, Yamagat S, Yamagata T: Ganglioside GM3 positively regulates Arhgdib, a Rho GTPase regulator, to suppress anchorage-independent growth via PI3K/AKT/mTOR pathway in mouse melanoma B16 cells. In preparation.